These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 9588878)
1. The pathogenesis of amyloidosis: understanding general principles. Westermark P Am J Pathol; 1998 May; 152(5):1125-7. PubMed ID: 9588878 [No Abstract] [Full Text] [Related]
2. Serum amyloid A and protein AA: molecular mechanisms of a transmissible amyloidosis. Westermark GT; Westermark P FEBS Lett; 2009 Aug; 583(16):2685-90. PubMed ID: 19393650 [TBL] [Abstract][Full Text] [Related]
4. [AL- and AA-amyloidosis (the status of the problem)]. Kochubeĭ LN; Vinogradova OM; Serov VV; Vasil'eva NA; Tomas NIu Klin Med (Mosk); 1988 Aug; 66(8):7-16. PubMed ID: 3057283 [No Abstract] [Full Text] [Related]
5. A mouse model for serum amyloid A amyloidosis. Kindy MS; de Beer FC Methods Enzymol; 1999; 309():701-16. PubMed ID: 10507056 [No Abstract] [Full Text] [Related]
7. Association of apolipoprotein E with murine amyloid A protein amyloid. Kindy MS; King AR; Perry G; de Beer MC; de Beer FC Lab Invest; 1995 Oct; 73(4):469-75. PubMed ID: 7474917 [TBL] [Abstract][Full Text] [Related]
8. Reduction in amyloid A amyloid formation in apolipoprotein-E-deficient mice. Kindy MS; Rader DJ Am J Pathol; 1998 May; 152(5):1387-95. PubMed ID: 9588907 [TBL] [Abstract][Full Text] [Related]
9. A serum AA-like protein as a common constituent of secondary amyloid fibrils. Westermark P; Sletten K Clin Exp Immunol; 1982 Sep; 49(3):725-31. PubMed ID: 7172504 [TBL] [Abstract][Full Text] [Related]
10. [Systemic amyloidosis associated with plasmacytoma. I. Present etiopathogenic findings]. Sakalová A; Tichý M; Horváth A; Hrubisko M Vnitr Lek; 1985 Jun; 31(6):572-6. PubMed ID: 4036024 [No Abstract] [Full Text] [Related]
11. [Systemic secondary AA amyloidosis]. Cadiñanos J; Costa R; Trujillo D; Real de Asúa D Med Clin (Barc); 2015 Apr; 144(7):324-30. PubMed ID: 25023854 [No Abstract] [Full Text] [Related]
12. Immunoglobulin allotypes are not involved in systemic amyloidosis. Ockhuizen T; Westra H; Bijzet J; Post J; van Leeuwen M; van Rijswijk M J Rheumatol; 1985 Aug; 12(4):742-6. PubMed ID: 3932652 [TBL] [Abstract][Full Text] [Related]
13. [Secondary amyloidosis]. Kito S; Itoga E; Ito T; Shinoda T; Yaguchi Y Nihon Rinsho; 1979 Sep; 37(9):3170-8. PubMed ID: 522264 [No Abstract] [Full Text] [Related]
14. Amyloid precursors and amyloidosis in rheumatoid arthritis. Cunnane G; Whitehead AS Baillieres Best Pract Res Clin Rheumatol; 1999 Dec; 13(4):615-28. PubMed ID: 10652643 [TBL] [Abstract][Full Text] [Related]
15. Are elevated serum amyloid A levels and amyloid-enhancing factor sufficient to induce inflammation-associated amyloid deposition? Kisilevsky R; Tan R; Subrahmanyan L; Snow A Appl Pathol; 1984; 2(6):308-15. PubMed ID: 6400464 [TBL] [Abstract][Full Text] [Related]
16. The pathogenesis and biochemistry of amyloidosis. Cohen AS; Connors LH J Pathol; 1987 Jan; 151(1):1-10. PubMed ID: 3550020 [TBL] [Abstract][Full Text] [Related]
17. The Runme Shaw memorial lecture. Amyloidoses of brain: transmissible and non-transmissible dementias. Gajdusek DC Ann Acad Med Singap; 1989 Jan; 18(1):98-9. PubMed ID: 2712527 [No Abstract] [Full Text] [Related]
19. Cloning of the familial Mediterranean fever gene: expectations for learning about the pathogenesis of amyloid A amyloidosis. Pras M Adv Nephrol Necker Hosp; 1998; 28():343-54. PubMed ID: 9889998 [No Abstract] [Full Text] [Related]
20. [Treatment and prognosis of secondary amyloidosis in the course of rheumatic disease]. Wiland P; Szechiński J Pol Arch Med Wewn; 2003 Jul; 110(1):797-802. PubMed ID: 14682217 [No Abstract] [Full Text] [Related] [Next] [New Search]